Job Description
Chimeric antigen receptor (CAR) expressing T cells have revolutionized the way that patients with B cell malignancies are treated. However, this personalized therapy is cumbersome and expensive, because T cells need to be collected from patients, genetically modified and re-infused. An ideal approach might be to create an “off-the-shelf” cell therapy product that can be given across MHC barriers.
The goal of this project is to identify key genes associated with immune recognition/rejection of CAR expressing NK and/or T cells. Manipulation of these genes would be expected to increase the in vivo persistence of MHC-disparate CAR T and NK cells. This will be tested using murine models and in human cells.